Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Chemoprevention
- Ovarian Cancer
- Central Nervous System Tumors
- Radiation Oncology
- Palliative Care
- Neoadjuvant Therapy
- General Oncology
- Head and Neck Oncology
Abstract
Citation: Clin Oncol. 2018;3(1):1481.DOI: 10.25107/2474-1663.1481
Investigation of Fiducial Marker Migration during the Treatment of Bladder Cancer with Image-Guided Radiation Therapy
Yulin Song, Ming Yan, Boris Mueller and Borys Mychalczak
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, USA
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, USA
*Correspondance to: Yulin Song
PDF Full Text Research Article | Open Access
Abstract:
Surgically implanted fiducial markers are widely used in the treatment of prostate, lung, and breast cancers with Image-Guided Radiation Therapy (IGRT). Fiducial markers are typically nonmigrating gold seeds with various dimensions for different site applications. To prevent markers from migrating in implanted soft tissue, their surfaces are cross-cut using a special knurling process. Implanted fiducial markers are felt to constitute a more reliable reference coordinate system than surrounding bony landmarks for a moving target and are used for point-based image registration. Studies have shown that fiducial markers are safe, stable, and can provide superior tumor tracking and targeting capability during both treatment planning and treatment delivery. At our institution, implanted fiducial markers are now being used for target volume localization in bladder cancer patients treated with IGRT. In this paper, we present our initial experience with this novel treatment procedure in terms of fiducial marker migration.
Keywords:
Bladder cancer; IGRT; IMRT; OBI; Fiducial marker
Cite the Article:
Song Y, Yan M, Mueller B, Mychalczak B. Investigation of Fiducial Marker Migration during the Treatment of Bladder Cancer with Image-Guided Radiation Therapy. Clin Oncol. 2018; 3: 1481.